PHARMA.AI Webinar Week
Discover how cutting-edge AI is transforming drug discovery and research!
November 19-21 | 11:30 - 12:30 pm EST
Omics Data Analysis.
Powered by Data-Driven Evidence
Powered by Data-Driven Evidence
60% Discount for Academia!
PandaOmics is Target ID
Actionable Target Identification
Discover disease targets with Omics data, publications, clinical trials, and more. Our AI prioritizes genes using our comprehensive multi-modal AI models based on your preferences for novelty, safety, and the presence of existing drugs. Upload your in-house Omics data to refine the ranking.
Target Evaluation
Once you have a short list of targets, PandaOmics helps you systematically evaluate all the background evidence on the discovered association.
Analyze molecular and text evidence connecting the target and the disease.
Analyze molecular and text evidence connecting the target and the disease.
Target Attention Prediction
Evaluate how the interest in a gene changes over the years. PandaOmics evaluates trends and forecasts attention growth in the upcoming years.
PandaOmics is Data Analysis
Omics Data Analysis
Use our normalized and annotated Omics data collections. Focus on data analysis and interpretation, not on pre-processing and hosting. Run target identification, indication, and compound prioritization; analyze differential expression to prioritize significantly under or over-expressed genes in sample groups.
Pathway Analysis
Find molecular processes affected by disease with our proprietary iPanda algorithm. Pathway analysis helps you gather insights into the disease process and its mechanisms. Use readily available Omics data or upload your custom data.
Biological Knowledge Graph
PandaOmics leverages large language models to provide insights into scientific knowledge about genes and diseases. We visualize relevant scientific papers with a Knowledge Graph to quickly find relevant papers.
Save time on literature reviews by using our ChatPandaGPT to get answers to your questions quickly.
Save time on literature reviews by using our ChatPandaGPT to get answers to your questions quickly.
Gene-Disease Association Report
Summarize all relevant information about gene-disease association into a comprehensive report. Understand relevant papers, Omics evidence, mechanism of action, competitive landscape, and suggested path to market.
PandaOmics is Knowledge Base
- 1.3M
Disease-specific
Omics samplesA full spectrum of Omics data generated by the scientific community - 15K
Clinical-stage
Compounds & BiologicsCompounds from Phase 1 to FDA-approved drugs - 3.2M
GrantsLife sciences research grant funding - 5.5M
PatentsPatents covering the life sciences industry - 998K
Clinical Trial RecordsExplore extra knowledge related
to the clinical trials design - 47M
PublicationsPublished biomedical research results
Case Studies
Hallmarks of aging-based dual-purpose disease and age-associated targets predicted using PandaOmics AI-powered discovery engine
In this study, we used a variety of target identification and prioritization techniques offered by the AI-powered PandaOmics platform, to propose a list of promising novel aging-associated targets that may be used for drug discovery.
Testimonials
“
We have had discussions with several AI startups and Insilico Medicine is the only company which provides excellent service not only with collaboration but also with software license. PandaOmics enabled us to analyze Microarray or RNAseq data easily and quickly. We are satisfied with its usability and the results generated from Insilico's software. We think PandaOmics is a worthwhile software for target identification. We also greatly appreciate their kind support. They are professionals, and always answer our questions quickly, precisely and kindly.
“
As we work to accelerate our understanding of diabetes and other diseases, PandaOmics is just the resource we sought to help us quickly access, analyze, visualize and interpret externally available data effectively to drive our research efforts. This new platform empowers our scientists to expedite biomarker identification, repurpose existing therapeutics and discover new drugs.
Dr. Daniel Robertson
Vice President of Digital Technology at the Indiana Biosciences Research Institute
Vice President of Digital Technology at the Indiana Biosciences Research Institute
Collaborations
Contact us
pandaomics@insilico.com
This website uses cookies to ensure you get the best experience
OK